Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage therapeutics company it exposes no public developer API surface.
Forty Seven * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immuno-Oncology, and Oncology.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/forty-seven: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: forty-seven
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- url: http://fortyseveninc.com
status: 307
note: declared website redirects to https://www.gilead.com/ — a different registrable domain (fortyseveninc.com -> gilead.com),
possible rename or acquisition (probed 2026-09-03, roadmap#169)
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven.png
name: Forty Seven *
description: Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion
research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal
antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic
syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired
by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage
therapeutics company it exposes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Immuno-Oncology
- Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: ParentCompany
url: https://apis.io/providers/gilead-sciences/
name: Gilead Sciences
x-relationship: acquired
x-evidence: Backed by GV, the company was acquired by Gilead Sciences in 2020 for roughly $4.
- type: DomainSecurity
url: security/forty-seven-domain-security.yml
- type: Website
url: http://fortyseveninc.com
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →